KRT8P36: A Potential Drug Target and Biomarker (G100418748)

Target Name: KRT8P36

NCBI ID: G100418748

KRT8P36

Other Name(s): Keratin 8 pseudogene 36 | keratin 8 pseudogene 36

KRT8P36: A Potential Drug Target and Biomarker

KRT8P36, also known as human Kallikrein-related peptidase 8 (KLK8), is a 8-kDa protein that is expressed in various tissues of the body, including the liver, pancreas, and blood vessels. It is a member of the serine proteases superfamily and is involved in the regulation of proteolytic enzymes, which are enzymes that break down other proteins. KRT8P36 has been identified as a potential drug target and biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

The Potential Role of KRT8P36 as a Drug Target

KRT8P36 has been shown to play a role in the regulation of proteolytic enzymes, which are involved in the breakdown of extracellular matrix (ECM) components and other proteins that contribute to tissue injury and inflammation. ECM is a complex mixture of extracellular matrix proteins, including collagen, elastin, and other carbohydrates, which are involved in maintaining tissue structure and providing mechanical support. The breakdown of ECM components by proteolytic enzymes contributes to tissue degradation and can lead to various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

KRT8P36 has been shown to regulate the activity of several proteolytic enzymes, including members of the serine proteases, such as collagenase, elastase, and matrix metalloproteinase (MMP). These enzymes are involved in the breakdown of extracellular matrix components and can contribute to tissue injury and disease. By regulating the activity of these enzymes, KRT8P36 may have a role in the development and progression of various diseases.

The Potential Role of KRT8P36 as a Biomarker

KRT8P36 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression. In addition, it has been shown to be involved in the regulation of inflammation, which is a key factor in the development of many diseases, including cancer.

KRT8P36 has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. These cytokines are involved in the recruitment of immune cells to the site of injury or infection, and can contribute to tissue damage and inflammation. By regulating the production of these cytokines, KRT8P36 may have a role in the development of inflammatory diseases, including cancer.

In addition, KRT8P36 has been shown to regulate the production of anti-inflammatory cytokines, such as IL-10. These cytokines are involved in the regulation of immune cell activity and can contribute to the anti-inflammatory response. By regulating the production of these cytokines, KRT8P36 may have a role in the development of chronic inflammatory diseases, including neurodegenerative diseases.

Conclusion

KRT8P36 is a protein that is involved in the regulation of proteolytic enzymes and has been identified as a potential drug target and biomarker for various diseases. Its role in the regulation of cellular processes that are important for cancer progression and inflammation makes it an attractive target for drug development. Further research is needed to fully understand the role of KRT8P36 in the development and progression of various diseases.

Protein Name: Keratin 8 Pseudogene 36

The "KRT8P36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT8P36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets